Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for CureVac (CVAC) over the last 2 years, with Q4 2024 value amounting to $12.4 million.

  • CureVac's Asset Writedowns and Impairment rose 32255.97% to $12.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.7 million, marking a year-over-year increase of 18146.51%. This contributed to the annual value of $37.7 million for FY2024, which is 132161.59% up from last year.
  • Latest data reveals that CureVac reported Asset Writedowns and Impairment of $12.4 million as of Q4 2024, which was up 32255.97% from -$5.6 million recorded in Q4 2023.
  • CureVac's Asset Writedowns and Impairment's 5-year high stood at $12.4 million during Q4 2024, with a 5-year trough of -$5.6 million in Q4 2023.